Federal Life Insurance Company Selects DXC Technology to Enhance Policy Buying Experience for Customers and Agents
28.4.2020 15:00:00 CEST | Business Wire | Press Release
Federal Life Insurance Company, based in Riverwoods, IL just northwest of Chicago, has gone live with DXC Assure for Life and Wealth to enhance the policy buying experience for their customers and agents, streamline key processes, and drive business growth. DXC’s solution is built on a scalable, cloud-based architecture, implemented on Amazon Web Services (AWS), and provided to Federal Life on an “as-a-Service” basis.
DXC Technology’s end-to-end insurance management solution streamlines new business acquisition for Federal Life by guiding producers through the data-gathering process, ensuring that all necessary information is collected at the point of sale. Information is automatically captured and submitted through a paperless, self-service process for immediate consideration. Additionally, Federal Life now benefits from straight-through processing of online policy requests with electronic signatures (e-signatures).
“Accelerating the application process and providing a superior customer experience that meets ― and exceeds ― our customers’ expectations is of critical importance to Federal Life Insurance Company,” said Bill Austin, CEO, Federal Life Group, Inc. “DXC’s platform, backed by DXC’s strong life and annuities expertise, will support us in providing a rich, easy-to-use online application experience on any device, and give us the flexibility to adapt to evolving customer needs quickly and cost effectively.”
DXC Assure for Life and Wealth encompasses electronic applications, forms management, policy administration, flexible product configuration, claims management and more. It helps insurers transform and reimagine customer-facing applications to deliver a high-quality user experience accessible on any device.
Federal Life, a longtime DXC customer, has plans to bring current and future products to DXC Assure for Life and Wealth deployed on AWS, leveraging it as a foundation to modernize the legacy IT landscape with new digital cloud-based capabilities.
“We are proud to continue our collaboration with Federal Life as it builds its digital business,” said Phil Ratcliff, vice president and general manager, Global Insurance, DXC Technology. “DXC Assure for Life and Wealth addresses key challenges that insurers are facing in today’s fast-changing market, and it will enable Federal Life to transform its business processes while improving new business speed-to-issue by streamlining and accelerating policy submission.”
DXC’s electronic application capability is a key component of DXC Assure for Life and Wealth. The overall solution accommodates contemporary life and wealth products, including term, traditional, variable and equity index life and annuity products. Business-focused API services dramatically simplify integration with customer, agent, third-party services and corporate systems. DXC Assure for Life and Wealth is an integrated solution that can be deployed in whole or in parts, enabling carriers to get into production quickly with only the components they need now.
DXC has served the global insurance industry for over 40 years, with more than 1,900 clients, active client communities and millions of policies administered on DXC’s life and annuity software and in business process services and solutions operations.
For more information on DXC Assure for Life and Wealth, click here.
About Federal Life Group, Inc.
Federal Life Group, Inc. (OTCMKTS: FLFG) is the parent of Federal Life Insurance Company (FLIC), an independently operated provider of quality life insurance and annuity products, incorporated in 1899. FLIC is headquartered in Riverwoods, Illinois, a suburb approximately thirty miles north of Chicago. FLIC is proud of its longstanding tradition of financial strength and stability. For more information, go to www.federallife.com.
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200428005011/en/
Contact information
Dana Greenstein, Corporate Media Relations, +1.914.607.7631, dgreenstein@dxc.com
Shailesh Murali, M&A and Investor Relations, +1.703.245.9700, shailesh.murali@dxc.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom